1) 日本排尿機能学会 男性下部尿路症状診療ガイドライン作成委員会(編) : 男性下部尿路症状診療ガイドライン. ブラックウェルパブリッシング, 東京, 2008
2) 日本排尿機能学会 女性下部尿路症状診療ガイドライン作成委員会(編) : 女性下部尿路症状診療ガイドライン. リッチヒルメディカル, 東京, 2013
3) 日本排尿機能学会 過活動膀胱診療ガイドライン作成委員会(編) : 過活動膀胱診療ガイドライン 第2版. リッチヒルメディカル, 東京, 2015
4) Schantz EJ and Johnson EA : Botulinum toxin : the story of its development for treatment of human disease. Perspect Biol Med 40 : 317─327, 1997
5) Chancellor MB, Fowler CJ, Apostolidis A, et al : Drug Insight : biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 5 : 319─328, 2008
6) Ouslander JG : Management of overactive bladder. N Engl J Med 350 : 786─799, 2004
7) da Silva CM and Cruz F : Has botulinum toxin therapy come of age : what do we know, what do we need to know, and should we use it? Curr Opin Urol 19 : 347─352, 2009
8) Sahai A, Khan MS and Dasgupta P : Efficacy of Botulinum toxin-A for treating idiopathic detrusor overactivity : results from a single center, randomized, double-blind, placebo controlled trail. J Urol 177 : 2231─2236, 2007
9) Brubaker L, Richter HE, Visco A, et al : Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180 : 217─222, 2008
10) Dmochowski R, Chapple C, Nitti VW, et al : Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder : a double-blind, placebo controlled, randomized, dose ranging trail. J Urol 184 : 2416─2422, 2010
11) Chapple C, Sievert KD, MacDiarmid S, et al : OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 64 : 49─56, 2013
12) Pannek J, Gocking K and Bersch U : Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 104 : 1246─1250, 2009
13) Okamura K, Nojiri Y, AmedaK, et al : Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder : early outcomes. Int J Urol 18 : 483─487, 2011
14) Okamura K, Takei M, Nojiri Y, et al : Twelve months follow-up injection of Onabotulinumtoxin A into vesical submucosa for refractory non-neurogenic overactive bladder. LUTS 5 : 55─59, 2013
15) Giannatoni A, Mearini E, Del Zingaro M, et al : Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity : clinical and urodynamic results. Eur Urol 55 : 705─711, 2009
16) Pannek J, Gocking K and Bersch U : Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 104 : 1246─1250, 2009
17) Khan S, Game X, Kalsi V, et al : Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol 185 : 1344─1349, 2011
18) Kuo HC, Liu HT, Chuang YC, et al : Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder : a single-center study. Eur Urol 65 : 1117─1124, 2014